Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies

NCT03051035 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT03051035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03051035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
April 6, 2017
Completion date
June 2, 2020
Enrollment
61 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant neoplasm